- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02800447
Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol
- To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma.
- To evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a confirmatory open-label, randomized, controlled, multicenter study. Recruited subjects are to be randomized to treatment group and controlled group, with ratio of 1:1. Treatment group will accept baseline BEACOPP regimen, while controlled group will accept ABVD regimen.
The study design consisted of a screening phase of 1 week, a treatment phase of 24 or 32 weeks, and a post treatment follow-up of at least 2 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is of age 18~65, both male and female;
- Newly pathologically diagnosed with classical Hodgkin's lymphoma (lymphocyte depletion type, lymphocyte rich type, nodular sclerosing type, and mixed cellularity type), who had not accepted previous treatment;
- Had stage IIB, III or IV disease, as assessed by the Ann Arbor classification;
- ECOG≤2, life expectancy ≥3 month;
- A negative serum pregnancy test required for sexually active women of childbearing potential;
- The subject voluntarily gives written informed consent to participate in the study.
Exclusion Criteria:
Hematopoietic function:
- Leukocyte <3,500/mm3(3.5×109/L)
- Neutrophils <1,500/mm3(1.5×109/L)
- Platelets <100,000/mm3(100×109/L)
- Intolerance to any of the active ingredients and/or excipients in the study medications;
- Severe central nervous system disorders and mental illness;
- Severe heart disease (congestive heart failure, uncontrolled hypertension, unstable coronary artery disease, or myocardial infarction, or severe arrhythmia). Echocardiography showed resting left ventricular ejection fraction (LVEF) < 50%);
- History of severe lung disease;
- AST or ALT>2.5×ULN,total bilirubin≥1.5×ULN,serum creatinine>1.5×ULN (for subject with liver metastases: AST or ALT>5xULN, total bilirubin ≥ 3xULN);
- Uncontrolled, systemic, active infection;
- Positive serology to HIV;
- HBsAg positive subjects can still be enrolled in the study, but researchers should follow "The consensus on the Treatment of Lymphoma with Hepatitis B Infections" to observe closely and/or provide prophylactic anti-HBV therapy (as per investigator's decision);
- Other previous or concomitant malignancy, except for basal cell carcinoma and/or cervical carcinoma in situ;
- The subject is receiving an investigational drug, or has participated in an investigational study within 30 days prior to screening;
- The subject is pregnant or lactating; or subjects of childbearing potential (both women and man subjects) do not want to take effective contraceptive measures during study period or within 3 months after study completes;
- Investigators believe subjects not suitable to participate in the study for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
baseline BEACOPP regimen
|
Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of: Cyclophosphamide injection: 650mg/m2, IV infusion, day 1; Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1; Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2,po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14
Other Names:
|
Active Comparator: controlled group
ABVD regimen
|
Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of: Doxorubicin hydrochloride injection:25mg/m2,IV infusion,day 1 and 15; Dacarbazine injection:375mg/m2,IV infusion,day 1 and 15; Bleomycin injection:10mg/m2,IV or IM,day 1 and 15; Vincristine injection:1.4mg/m2
(single maximum dose is 2mg), IV infusion,day 1 and 15;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate (ORR)
Time Frame: 45 months
|
Compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for in patients with advanced Hodgkin's lymphoma.
|
45 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety as measured by changes of vital signs, ECG and AE number
Time Frame: 45 months
|
45 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Zhaoke-NTL-2015-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hodgkin's Lymphoma
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
British Columbia Cancer AgencyHoffmann-La RocheActive, not recruitingLymphoma, Non-Hodgkin | Advanced Stage Diffuse Large B-Cell Non-Hodgkin's LymphomaCanada
-
Bristol-Myers SquibbTerminatedAdvanced Solid Tumors | Advanced B-cell NHLUnited States, France, Spain, Germany
-
Alaunos TherapeuticsUnknownAdvanced CancerUnited States
-
Spectrum Pharmaceuticals, IncTerminatedNon-Hodgkin's Lymphoma | Advanced Solid TumorsUnited States
-
BayerCompletedNon-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Advanced Solid TumorUnited States, Canada, China, Japan, Singapore, United Kingdom, Switzerland
-
Chinese PLA General HospitalRecruitingStudy of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsAdvanced Solid Tumors | Relapsed/Refractory Non-Hodgkin LymphomaChina
-
Eucure (Beijing) Biopharma Co., LtdRecruitingAdvanced Solid Tumors | Relapsed Or Refractory Non-Hodgkin LymphomaChina
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
Clinical Trials on Natulan
-
Ospedale Santa Croce-Carle CuneoConsorzio Mario Negri Sud; GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)UnknownHODGKIN LYMPHOMAIsrael, Italy
-
Fondazione MichelangeloCompleted
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCCompletedAIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Diffuse Mixed Cell Lymphoma | AIDS-related Diffuse Small Cleaved Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Lymphoblastic Lymphoma | AIDS-related Small Noncleaved... and other conditionsZimbabwe, Kenya
-
National Cancer Institute (NCI)RecruitingLugano Classification Limited Stage Hodgkin Lymphoma AJCC v8United States, Puerto Rico, Canada